Swing,

The Type II trial is for superiority but if we can't beat a placebo,we're in trouble.

Hakan:

"Our pivotal Type 2 study, the MKC-175, was initiated on schedule following the start of the Type 1 pivotal study. Site activation is well underway, with 35 U.S. sites already established and with additional sites currently being activated. The MKC-175 investigator meeting in Russia was held last week and Russian site activation and recruitment are now beginning. This is to be a superiority study in early-stage Type 2 patients failing on Metformin or Metformin plus another oral drug.

AFREZZA is provided in 1 arm. The other arm is Technosphere placebo without insulin, and each arm is scheduled to finish with 123 patients."

http://seekingalpha.com/article/385161-mannkind-s-ceo-discusses-q4-2011-results-earnings-call-transcript?find=superiority&all=false